Joyous says at-home ketamine care has reached 90,000 patients

By AI, Created 11:25 PM UTC, May 22, 2026, /AGP/ – Joyous Public Benefit Corporation said its at-home microdose ketamine platform has treated more than 90,000 patients in 28 U.S. states since 2022. The milestone underscores demand for lower-cost, telehealth-based mental health care as the company reports more than 17 million doses delivered.

Why it matters: - Joyous is positioning at-home ketamine treatment as a lower-cost alternative to in-clinic psychiatric care. - The model could widen access for patients who struggle with affordability, scheduling or clinic availability. - Joyous says more than 17 million very-low-dose ketamine treatments have been delivered since the company launched in 2022. - Plans start at $129 per month, and Joyous accepts HSA and FSA payments.

What happened: - Joyous Public Benefit Corporation said more than 90,000 patients across 28 U.S. states have received care through its platform since launch. - The Foster City, California-based telehealth provider announced the milestone on May 22, 2026. - The company provides at-home microdose ketamine treatment for depression and anxiety under the care of licensed medical providers.

The details: - Joyous treatment uses psycholytic, very low doses of ketamine paired with digital support tools. - The support package includes psychology-based educational courses and a peer support community platform. - Internal patient data from the past 12 months shows more than 76% of Joyous patients previously tried antidepressants. - More than 83% of patients report currently being in therapy or having participated in therapy previously. - Joyous says a growing share of patients cite affordability and accessibility as reasons for using telehealth-based treatment. - Many patients enter care after years of struggling with anxiety, depression, burnout or unsuccessful prior treatment attempts. - Joyous screens prospective patients against medical and psychiatric exclusion criteria before treatment starts. - About 1 in 10 prospective patients are screened out or paused for additional clinical review. - Patients receive ongoing provider oversight and regular mental health monitoring throughout care. - Joyous says individual experiences vary and does not guarantee specific outcomes. - Information on risks, side effects and medical disclaimers is available at disclaimers. - Additional information on patient outcomes, treatment protocols and program history is available at the science page.

Between the lines: - The results point to growing consumer interest in mental health treatment that avoids the cost and logistics of clinic-based ketamine therapy. - Dr. Bobbi Leben, Joyous co-founder and chief medical officer, said patients are increasingly seeking alternatives after feeling underserved by traditional mental health systems. - Leben also said psychedelic treatment is moving beyond boutique clinics into broader healthcare accessibility. - Ketamine is a dissociative anesthetic that was FDA-approved in 1970 and is commonly prescribed off-label for depression and anxiety.

What’s next: - Joyous said spokespeople are available for interviews at press@joyous.team. - The company continues to market at-home telehealth care for adults seeking support for depression and anxiety. - Joyous says outcomes will vary and patients should review the company’s safety information before treatment.